Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function

Brian J. Sandri, Laia Masvidal, Carl Murie, Margarita Bartish, Svetlana Avdulov, Lee Ann Higgins, Todd Markowski, Mark Peterson, Jonas Bergh, Ping Yang, Charlotte Rolny, Andrew Harold Limper, Timothy J. Griffin, Peter B. Bitterman, Chris H. Wendt, Ola Larsson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rationale: Chronic obstructive pulmonary disease is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that lung stromal cells activate pathological gene expression programs that support oncogenesis.Objectives: To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer.Methods: The study included subjects with and without lung cancer across a spectrum of lung-function values. We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome.Measurements and Main Results: Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation modulating protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms that drove these cancer-associated translation programs differed based on lung function. In subjects with normal to mildly impaired lung function, the mammalian target of rapamycin (mTOR) pathway served as an upstream driver, whereas in subjects with severe airflow obstruction, pathways downstream of pathological extracellular matrix emerged. Consistent with a role during cancer initiation, both the mTOR and extracellular matrix gene expression programs paralleled the activation of previously identified procancer secretomes. Furthermore, an in situ examination of lung tissue showed that stromal fibroblasts expressed cancer-associated proteins from two procancer secretomes: one that included IL-6 (in cases of mild or no airflow obstruction), and one that included BMP1 (in cases of severe airflow obstruction).Conclusions: Two distinct stromal gene expression programs that promote cancer initiation are activated in patients with lung cancer depending on lung function. Our work has implications both for screening strategies and for personalized approaches to cancer treatment.

Original languageEnglish (US)
Pages (from-to)348-358
Number of pages11
JournalAmerican journal of respiratory and critical care medicine
Volume200
Issue number3
DOIs
StatePublished - Aug 1 2019

Fingerprint

Gene Expression
Lung
Lung Neoplasms
Neoplasms
Sirolimus
Extracellular Matrix
Neoplasm Genes
Protein Biosynthesis
Proteome
Stromal Cells
Transcriptome
Chronic Obstructive Pulmonary Disease
Interleukin-6
Carcinogenesis
Proteins
Messenger RNA
Therapeutics

Keywords

  • cancer
  • COPD
  • fibroblast
  • secretome
  • translation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Sandri, B. J., Masvidal, L., Murie, C., Bartish, M., Avdulov, S., Higgins, L. A., ... Larsson, O. (2019). Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. American journal of respiratory and critical care medicine, 200(3), 348-358. https://doi.org/10.1164/rccm.201801-0080OC

Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. / Sandri, Brian J.; Masvidal, Laia; Murie, Carl; Bartish, Margarita; Avdulov, Svetlana; Higgins, Lee Ann; Markowski, Todd; Peterson, Mark; Bergh, Jonas; Yang, Ping; Rolny, Charlotte; Limper, Andrew Harold; Griffin, Timothy J.; Bitterman, Peter B.; Wendt, Chris H.; Larsson, Ola.

In: American journal of respiratory and critical care medicine, Vol. 200, No. 3, 01.08.2019, p. 348-358.

Research output: Contribution to journalArticle

Sandri, BJ, Masvidal, L, Murie, C, Bartish, M, Avdulov, S, Higgins, LA, Markowski, T, Peterson, M, Bergh, J, Yang, P, Rolny, C, Limper, AH, Griffin, TJ, Bitterman, PB, Wendt, CH & Larsson, O 2019, 'Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function', American journal of respiratory and critical care medicine, vol. 200, no. 3, pp. 348-358. https://doi.org/10.1164/rccm.201801-0080OC
Sandri, Brian J. ; Masvidal, Laia ; Murie, Carl ; Bartish, Margarita ; Avdulov, Svetlana ; Higgins, Lee Ann ; Markowski, Todd ; Peterson, Mark ; Bergh, Jonas ; Yang, Ping ; Rolny, Charlotte ; Limper, Andrew Harold ; Griffin, Timothy J. ; Bitterman, Peter B. ; Wendt, Chris H. ; Larsson, Ola. / Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. In: American journal of respiratory and critical care medicine. 2019 ; Vol. 200, No. 3. pp. 348-358.
@article{07f4675fd3d0405b88b4c0b5cce4f521,
title = "Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function",
abstract = "Rationale: Chronic obstructive pulmonary disease is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that lung stromal cells activate pathological gene expression programs that support oncogenesis.Objectives: To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer.Methods: The study included subjects with and without lung cancer across a spectrum of lung-function values. We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome.Measurements and Main Results: Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation modulating protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms that drove these cancer-associated translation programs differed based on lung function. In subjects with normal to mildly impaired lung function, the mammalian target of rapamycin (mTOR) pathway served as an upstream driver, whereas in subjects with severe airflow obstruction, pathways downstream of pathological extracellular matrix emerged. Consistent with a role during cancer initiation, both the mTOR and extracellular matrix gene expression programs paralleled the activation of previously identified procancer secretomes. Furthermore, an in situ examination of lung tissue showed that stromal fibroblasts expressed cancer-associated proteins from two procancer secretomes: one that included IL-6 (in cases of mild or no airflow obstruction), and one that included BMP1 (in cases of severe airflow obstruction).Conclusions: Two distinct stromal gene expression programs that promote cancer initiation are activated in patients with lung cancer depending on lung function. Our work has implications both for screening strategies and for personalized approaches to cancer treatment.",
keywords = "cancer, COPD, fibroblast, secretome, translation",
author = "Sandri, {Brian J.} and Laia Masvidal and Carl Murie and Margarita Bartish and Svetlana Avdulov and Higgins, {Lee Ann} and Todd Markowski and Mark Peterson and Jonas Bergh and Ping Yang and Charlotte Rolny and Limper, {Andrew Harold} and Griffin, {Timothy J.} and Bitterman, {Peter B.} and Wendt, {Chris H.} and Ola Larsson",
year = "2019",
month = "8",
day = "1",
doi = "10.1164/rccm.201801-0080OC",
language = "English (US)",
volume = "200",
pages = "348--358",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function

AU - Sandri, Brian J.

AU - Masvidal, Laia

AU - Murie, Carl

AU - Bartish, Margarita

AU - Avdulov, Svetlana

AU - Higgins, Lee Ann

AU - Markowski, Todd

AU - Peterson, Mark

AU - Bergh, Jonas

AU - Yang, Ping

AU - Rolny, Charlotte

AU - Limper, Andrew Harold

AU - Griffin, Timothy J.

AU - Bitterman, Peter B.

AU - Wendt, Chris H.

AU - Larsson, Ola

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Rationale: Chronic obstructive pulmonary disease is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that lung stromal cells activate pathological gene expression programs that support oncogenesis.Objectives: To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer.Methods: The study included subjects with and without lung cancer across a spectrum of lung-function values. We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome.Measurements and Main Results: Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation modulating protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms that drove these cancer-associated translation programs differed based on lung function. In subjects with normal to mildly impaired lung function, the mammalian target of rapamycin (mTOR) pathway served as an upstream driver, whereas in subjects with severe airflow obstruction, pathways downstream of pathological extracellular matrix emerged. Consistent with a role during cancer initiation, both the mTOR and extracellular matrix gene expression programs paralleled the activation of previously identified procancer secretomes. Furthermore, an in situ examination of lung tissue showed that stromal fibroblasts expressed cancer-associated proteins from two procancer secretomes: one that included IL-6 (in cases of mild or no airflow obstruction), and one that included BMP1 (in cases of severe airflow obstruction).Conclusions: Two distinct stromal gene expression programs that promote cancer initiation are activated in patients with lung cancer depending on lung function. Our work has implications both for screening strategies and for personalized approaches to cancer treatment.

AB - Rationale: Chronic obstructive pulmonary disease is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that lung stromal cells activate pathological gene expression programs that support oncogenesis.Objectives: To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer.Methods: The study included subjects with and without lung cancer across a spectrum of lung-function values. We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome.Measurements and Main Results: Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation modulating protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms that drove these cancer-associated translation programs differed based on lung function. In subjects with normal to mildly impaired lung function, the mammalian target of rapamycin (mTOR) pathway served as an upstream driver, whereas in subjects with severe airflow obstruction, pathways downstream of pathological extracellular matrix emerged. Consistent with a role during cancer initiation, both the mTOR and extracellular matrix gene expression programs paralleled the activation of previously identified procancer secretomes. Furthermore, an in situ examination of lung tissue showed that stromal fibroblasts expressed cancer-associated proteins from two procancer secretomes: one that included IL-6 (in cases of mild or no airflow obstruction), and one that included BMP1 (in cases of severe airflow obstruction).Conclusions: Two distinct stromal gene expression programs that promote cancer initiation are activated in patients with lung cancer depending on lung function. Our work has implications both for screening strategies and for personalized approaches to cancer treatment.

KW - cancer

KW - COPD

KW - fibroblast

KW - secretome

KW - translation

UR - http://www.scopus.com/inward/record.url?scp=85065747231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065747231&partnerID=8YFLogxK

U2 - 10.1164/rccm.201801-0080OC

DO - 10.1164/rccm.201801-0080OC

M3 - Article

VL - 200

SP - 348

EP - 358

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -